121 related articles for article (PubMed ID: 21711232)
1. Urokinase receptor (uPAR) ligand based recombinant toxins for human cancer therapy.
de Virgilio M; Silvestris F
Curr Pharm Des; 2011; 17(19):1979-83. PubMed ID: 21711232
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
3. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor.
Rajagopal V; Kreitman RJ
J Biol Chem; 2000 Mar; 275(11):7566-73. PubMed ID: 10713063
[TBL] [Abstract][Full Text] [Related]
4. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
Zuppone S; Assalini C; Minici C; Bertagnoli S; Branduardi P; Degano M; Fabbrini MS; Montorsi F; Salonia A; Vago R
Sci Rep; 2020 Feb; 10(1):2521. PubMed ID: 32054892
[TBL] [Abstract][Full Text] [Related]
5. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model.
Todhunter DA; Hall WA; Rustamzadeh E; Shu Y; Doumbia SO; Vallera DA
Protein Eng Des Sel; 2004 Feb; 17(2):157-64. PubMed ID: 15047912
[TBL] [Abstract][Full Text] [Related]
6. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated.
Fabbrini MS; Carpani D; Bello-Rivero I; Soria MR
FASEB J; 1997 Nov; 11(13):1169-76. PubMed ID: 9367352
[TBL] [Abstract][Full Text] [Related]
7. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT.
Vallera DA; Li C; Jin N; Panoskaltsis-Mortari A; Hall WA
J Natl Cancer Inst; 2002 Apr; 94(8):597-606. PubMed ID: 11959893
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
9. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
10. Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera.
Errico Provenzano A; Posteri R; Giansanti F; Angelucci F; Flavell SU; Flavell DJ; Fabbrini MS; Porro D; Ippoliti R; Ceriotti A; Branduardi P; Vago R
Microb Cell Fact; 2016 Nov; 15(1):194. PubMed ID: 27842546
[TBL] [Abstract][Full Text] [Related]
11. Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism.
Ippoliti R; Lendaro E; Benedetti PA; Torrisi MR; Belleudi F; Carpani D; Soria MR; Fabbrini MS
FASEB J; 2000 Jul; 14(10):1335-44. PubMed ID: 10877826
[TBL] [Abstract][Full Text] [Related]
12. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
13. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells.
Ramage JG; Vallera DA; Black JH; Aplan PD; Kees UR; Frankel AE
Leuk Res; 2003 Jan; 27(1):79-84. PubMed ID: 12479856
[TBL] [Abstract][Full Text] [Related]
14. Urokinase plasminogen activator system as a potential target for cancer therapy.
Mekkawy AH; Morris DL; Pourgholami MH
Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
[TBL] [Abstract][Full Text] [Related]
15. Nonproteolytic role for the urokinase receptor in cellular migration in vivo.
Waltz DA; Fujita RM; Yang X; Natkin L; Zhuo S; Gerard CJ; Rosenberg S; Chapman HA
Am J Respir Cell Mol Biol; 2000 Mar; 22(3):316-22. PubMed ID: 10696068
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
[TBL] [Abstract][Full Text] [Related]
17. Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors.
Oh F; Modiano JF; Bachanova V; Vallera DA
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32630411
[TBL] [Abstract][Full Text] [Related]
18. Modulators of the urokinase-type plasminogen activation system for cancer.
Hildenbrand R; Allgayer H; Marx A; Stroebel P
Expert Opin Investig Drugs; 2010 May; 19(5):641-52. PubMed ID: 20402599
[TBL] [Abstract][Full Text] [Related]
19. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
20. Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.
Ploug M; Rahbek-Nielsen H; Ellis V; Roepstorff P; Danø K
Biochemistry; 1995 Oct; 34(39):12524-34. PubMed ID: 7548000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
